Rescindment of the VAI status for Unit IV just three days after it was issued (February 18, 2020) is indeed a unique case with negative sentimental implications. Unit IV is a critical plant for the company, given most of its pending injectables are filed from this plant. Injectable segment is one of the key drivers for the company's future growth and margins. OAI status for Unit VII just two weeks back and now the rescinded VAI status for Unit IV from USFDA does not bode well for the company. The lingering cGMP issues and, in particular, issues including some important plants like Unit IV and Unit VII...